|
JP6400470B2
(ja)
|
2011-05-16 |
2018-10-03 |
ジェネロン（シャンハイ）コーポレイション リミテッド |
多重特異性Ｆａｂ融合タンパク質および使用法
|
|
EP3805371A1
(en)
|
2014-05-15 |
2021-04-14 |
National University of Singapore |
Modified natural killer cells and uses thereof
|
|
EP3064507A1
(en)
*
|
2015-03-06 |
2016-09-07 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
|
|
CN112574316A
(zh)
|
2015-07-02 |
2021-03-30 |
博际生物医药科技(杭州)有限公司 |
用于肿瘤靶向治疗的白细胞介素-15融合蛋白
|
|
WO2017157305A1
(en)
|
2016-03-15 |
2017-09-21 |
Generon (Shanghai) Corporation Ltd. |
Multispecific fab fusion proteins and use thereof
|
|
CN109715196A
(zh)
|
2016-06-13 |
2019-05-03 |
转矩医疗股份有限公司 |
用于促进免疫细胞功能的组合物和方法
|
|
MX2019004327A
(es)
|
2016-10-14 |
2019-10-14 |
Xencor Inc |
Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
|
|
US11629340B2
(en)
|
2017-03-03 |
2023-04-18 |
Obsidian Therapeutics, Inc. |
DHFR tunable protein regulation
|
|
CN117363636A
(zh)
|
2017-03-27 |
2024-01-09 |
新加坡国立大学 |
一种编码嵌合受体的多核苷酸
|
|
MX2019011570A
(es)
|
2017-03-27 |
2019-11-18 |
Nat Univ Singapore |
Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
|
|
KR102461885B1
(ko)
|
2017-04-03 |
2022-11-03 |
에프. 호프만-라 로슈 아게 |
항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
|
|
AU2018291497A1
(en)
|
2017-06-30 |
2020-01-16 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
|
|
WO2019032628A1
(en)
|
2017-08-07 |
2019-02-14 |
The Regents Of The University Of California |
GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS
|
|
CA3074826A1
(en)
|
2017-09-05 |
2019-03-14 |
Torque Therapeutics, Inc. |
Therapeutic protein compositions and methods of making and using the same
|
|
AU2018338786A1
(en)
*
|
2017-09-29 |
2020-04-16 |
Nantcell, Inc. |
Antigenic proteins and methods therefor
|
|
JP7360174B2
(ja)
|
2018-02-09 |
2023-10-12 |
ナショナル ユニヴァーシティー オブ シンガポール |
ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
|
|
AU2019224159B2
(en)
*
|
2018-02-26 |
2025-05-29 |
Sanofi |
IL-15 conjugates and uses thereof
|
|
MX387358B
(es)
*
|
2018-02-28 |
2025-03-18 |
Pfizer |
Variantes de il-15 y usos de las mismas
|
|
US12441787B2
(en)
|
2018-04-02 |
2025-10-14 |
National University Of Singapore |
Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
|
|
CA3097625A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
|
|
CA3097593A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
WO2019204646A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
|
|
KR20210003814A
(ko)
|
2018-04-18 |
2021-01-12 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
|
|
WO2019246142A1
(en)
*
|
2018-06-18 |
2019-12-26 |
Haiming Chen |
Soluble bispecific fusion proteins for cancer immunotherapy
|
|
CA3102036A1
(en)
*
|
2018-06-18 |
2019-12-26 |
Anwita Biosciences, Inc. |
Cytokine fusion proteins and uses thereof
|
|
WO2020044239A1
(en)
|
2018-08-29 |
2020-03-05 |
National University Of Singapore |
A method to specifically stimulate survival and expansion of genetically-modified immune cells
|
|
EP3847196A4
(en)
|
2018-09-07 |
2023-01-04 |
ITabMed (HK) Limited |
BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
|
|
CN109207430A
(zh)
*
|
2018-09-25 |
2019-01-15 |
华东师范大学 |
一种嵌合抗原受体nk细胞及其制备方法和应用
|
|
CN113286812B
(zh)
|
2018-09-27 |
2025-05-30 |
西里欧发展公司 |
掩蔽型细胞因子多肽
|
|
JP6935383B2
(ja)
*
|
2018-09-27 |
2021-09-15 |
公益財団法人実験動物中央研究所 |
免疫不全マウス
|
|
CA3116188A1
(en)
|
2018-10-12 |
2020-04-16 |
Xencor, Inc. |
Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
|
|
CN113226340A
(zh)
|
2018-11-26 |
2021-08-06 |
恩卡尔塔公司 |
同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
|
|
US11618776B2
(en)
|
2018-12-20 |
2023-04-04 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
|
|
WO2020132810A1
(en)
|
2018-12-24 |
2020-07-02 |
Generon (Shanghai) Corporation Ltd. |
Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
|
|
KR20210137085A
(ko)
|
2019-03-05 |
2021-11-17 |
엔카르타, 인크. |
Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
|
|
SG11202111409YA
(en)
|
2019-05-20 |
2021-12-30 |
Cytune Pharma |
IL-2/IL-15Rßy AGONIST DOSING REGIMENS FOR TREATING CANCER OR INFECTIOUS DISEASES
|
|
AU2020315213A1
(en)
*
|
2019-07-17 |
2022-02-03 |
National University Of Singapore |
Functional binders synthesized and secreted by immune cells
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
CN111690068B
(zh)
*
|
2019-11-13 |
2022-04-19 |
中国科学技术大学 |
一种IL-15/SuIL-15Rα-dFc-γ4复合体蛋白及其构造方法、应用
|
|
EP3822288A1
(en)
|
2019-11-18 |
2021-05-19 |
Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts |
Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
|
|
CN114761433B
(zh)
*
|
2019-12-11 |
2025-07-29 |
上海复宏汉霖生物技术股份有限公司 |
一种抗Claudin18.2单克隆抗体、其制备方法及用途
|
|
CA3193073A1
(en)
*
|
2020-09-17 |
2022-03-24 |
Liping SONG |
Bispecific recombinant protein and use thereof
|
|
KR20230096047A
(ko)
|
2020-10-26 |
2023-06-29 |
싸이튠 파마 |
비흑색종 피부암 치료용 IL-2/IL-15Rβγ 작용제
|
|
WO2022090203A1
(en)
|
2020-10-26 |
2022-05-05 |
Cytune Pharma |
IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA
|
|
EP4251187A4
(en)
|
2020-11-25 |
2025-09-10 |
Xilio Dev Inc |
TUMOR-SPECIFIC CLASSIBLE LINKERS
|
|
CN116635407A
(zh)
*
|
2020-12-23 |
2023-08-22 |
瑞泽恩制药公司 |
编码锚修饰的抗体的核酸以及其用途
|
|
JP2024526080A
(ja)
|
2021-06-23 |
2024-07-17 |
サイチューン ファーマ |
インターロイキン１５多様体
|
|
WO2023280287A1
(en)
*
|
2021-07-09 |
2023-01-12 |
Nanjing Legend Biotech Co., Ltd. |
Interleukin-15 variants and uses thereof
|
|
US20240350589A1
(en)
|
2021-08-13 |
2024-10-24 |
Cytune Pharma |
Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer
|
|
CN113956346B
(zh)
*
|
2021-10-26 |
2024-03-01 |
西安龙腾景云生物科技有限公司 |
一种重组白介素-15变体
|
|
CN115141283A
(zh)
*
|
2022-03-10 |
2022-10-04 |
厦门柏慈生物科技有限公司 |
一种融合蛋白、制备方法及其应用
|
|
CN119997975A
(zh)
*
|
2022-10-19 |
2025-05-13 |
安斯泰来制药株式会社 |
抗cldn4-抗cd137双特异性抗体通过与pd-1信号抑制剂的组合在癌症治疗中的应用
|
|
CN120693344A
(zh)
*
|
2023-02-14 |
2025-09-23 |
德国癌症研究公共权益基金会 |
具有改善的特性的il-15融合蛋白
|
|
WO2024215987A1
(en)
|
2023-04-14 |
2024-10-17 |
Sotio Biotech Inc. |
IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES
|
|
EP4694916A1
(en)
|
2023-04-14 |
2026-02-18 |
SOTIO Biotech Inc. |
Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists
|
|
WO2025147512A1
(en)
*
|
2024-01-02 |
2025-07-10 |
Eli Lilly And Company |
Immunogenicity assessment platform for biotherapeutic proteins
|
|
WO2025151752A1
(en)
|
2024-01-10 |
2025-07-17 |
Xilio Development, Inc. |
Masked il-2 cytokines and methods of use thereof
|
|
WO2025222129A2
(en)
*
|
2024-04-19 |
2025-10-23 |
Mozart Therapeutics, Inc. |
Engineered cytokines and targeted cytokine delivery
|